Galderma Group (SWX:GALD) has just raised its full-year 2026 net sales growth guidance to a range of 19% to 21% at constant currency, after reporting 24.6% year-on-year net sales growth in the first half.
Galderma Group's recent guidance lift comes after a mixed year for the stock, with the share price up 1.96% on the day and 3.63% over the past week, but down 6.00% over 30 days and 8.01% over 90 days. The 1 year total shareholder return of 14.13% points to stronger longer term momentum around its SMI inclusion and recent product news.
Scan Galderma Group's peers benefiting from similar healthcare momentum by reviewing the hand picked 131 healthcare AI stocks that could be setting up their next move.
Galderma Group is pricing in a mix of strong guidance and a choppy chart. Are investors mainly reacting to the upgraded sales outlook, or has sentiment simply reset around a still evolving dermatology story?
Most Popular Narrative: 17% Undervalued
Against a last close of CHF161.25, the most followed narrative pegs Galderma Group's fair value at CHF193.27, which points to a valuation gap that investors now weigh against upgraded sales guidance and a busy launch calendar.
The strong uptake and market share gains of newly launched products like Nemluvio and Relfydess, driven by their differentiated clinical profiles and positive physician reception, are likely to accelerate Galderma's top-line growth and expand the addressable market, especially as global population aging and heightened focus on appearance drive continued demand for dermatological and aesthetic treatments, positively impacting future revenues.
See why 11 investors see Galderma Group as 17% undervalued .
Result: Fair Value of CHF193.27 (UNDERVALUED)
Still, the Galderma Group story leans on a narrow set of blockbusters and faces softer injectable aesthetics demand, so regulatory setbacks or slower uptake could quickly challenge this upbeat narrative.
Find out about the key risks to this Galderma Group narrative .
Another View On Galderma Group's Valuation
That 17% undervaluation narrative leans heavily on future growth. On today's numbers, Galderma Group trades on a P/E of 53.1x, which is far above the European pharmaceuticals average of 19.6x and the fair ratio of 39.7x. That gap implies valuation risk if enthusiasm cools.
For a closer look at how that price tag compares with peers, our valuation breakdown goes deeper into the P/E gap and what it could mean for future returns: See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Feeling cautiously optimistic after Galderma Group's guidance lift and valuation gap debate? Act while the story is still forming by weighing those 4 key rewards
Looking for more investment ideas beyond Galderma Group?
If Galderma Group has caught your attention, broaden your watchlist now by scanning other opportunities that match clear fundamentals and focused return profiles.
-
Target potential mispricing by reviewing companies flagged as 174 high quality undervalued stocks before the crowd fully catches on.
-
Prioritise resilience first and see which businesses pass the toughness test in our 229 resilient stocks with low risk scores .
-
Hunt for overlooked quality by scanning the 616 high quality undiscovered gems that might not yet be on every investor's radar.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include GALD.SW .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
